A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC-4401C in Healthy Subjects

The purpose of this study is to evaluate the safety, tolerability and characterize the PK, PD f\profile.

Study Overview

• Status: Completed
• Conditions: Healthy Male
• Intervention / Treatment: Drug: GCC-4401; Drug: GCC-4401C

Detailed Description

The primary objective of this study is to investigate the safety and tolerability following administration of single ascending doses of GCC4401C in healthy male subjects; and the secondary objective of this study is to characterize the single-dose PK profile after oral administration of GCC-4401C, and to determine an appropriate dose range and dosing regimen of oral GCC-4401C for subsequent clinical trials.

• Study Type: Interventional
• Enrollment (Actual): 48
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Kansas
    • Overland Park, Kansas, United States, 66211
      • Quintiles Phase1 Unit

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. Capable of understanding and complying with the requirements of the study and have signed the informed consent form (ICF);
2. Normal healthy males between 18 and 55 years of age, inclusive, at the time of consent;
3. A body mass index (BMI) of at least 18.5 kg/m2 but no more than 30 kg/m2 (BMI is defined as the subject's weight in kilograms divided by the square root of the subject's height in meters);
4. In general good health based on screening medical history, physical examination (defined as the absence of any clinically significant abnormalities), vital signs, and clinical laboratory values (hematology, serum chemistry, and urinalysis);
5. Have a normal ECG (defined as Fridericia's correction for QT interval [QTcF] less than or equal to 450 ms) at screening, Day -1 and Day 1, predose (baseline). Repeat ECG measurements will be allowed at the baseline assessment for QTcF values above 450 ms and the average will be used to assess eligibility.
6. Male subjects must use barrier contraception during sexual intercourse, ie, condoms, from the first day of dosing until 3 months after the last dosing with GCC-4401C; and
7. Nonsmokers (defined as not having smoked or used any nicotine containing products for at least 1 month, and having a urine cotinine less than 400 ng/mL).

Exclusion Criteria:

Subjects presenting with any of the following will not be entered into the study:

1. Have clinically significant abnormal history, physical findings, or laboratory values at the prestudy screening assessment that could interfere with the objectives of the study or the safety of the subjects;

2. Have any of the following, which may put them at increased risk with anticoagulant use:

   • family history or personal history of bleeding disorders or diseases/syndromes that can either alter or increase the propensity for bleeding;
   • severe trauma, fracture, major surgery, or biopsy of a parenchymal organ within the past 3 months;
   • endoscopic peptic-ulcer disease within the past 3 years or clinically significant gastrointestinal, genitourinary, or gum bleeding within the past 3 months;
   • a personal history of vascular abnormalities including aneurysms; a personal history of severe hemorrhage, hematemesis, melena, hemoptysis, severe epistaxis, severe thrombocytopenia, intracranial hemorrhage; or rectal bleeding within 3 months prior to screening;
   • any history of thrombotic or hemorrhagic stroke;
   • clinically significant laboratory abnormalities (hemoglobin less than 12.0 g/dL, prolonged PT or INR, prolonged aPTT, elevated liver enzymes, elevated serum creatinine or blood urea nitrogen (BUN) which is considered clinically significant by the Investigator, or platelet count less than 150,000/mm3 or greater than 600,000/mm3). Mildly elevated BUN with normal serum creatinine values which are determined not to be clinical significant by the Investigator are permitted. These significant laboratory values may be repeated for confirmation; or
   • any other contraindication to anticoagulant treatment, or increased bleeding risk, as judged by the Investigator.
3. Have known positive test for hepatitis B surface antigen, hepatitis C antibody, human immunodeficiency virus (HIV) 1, or HIV 2;
4. Are considering or scheduled to undergo any surgical procedure during the study;
5. Have received an investigational product within 30 days prior to dosing;
6. Presence or history of severe adverse reaction to any drug;
7. Involvement in the planning and/or conduct of the study;
8. Positive urine drug screen or urine alcohol screen at medical screening or check-in;
9. History of alcohol, drug, or substance abuse, as defined in Diagnostic and Statistical Manual of Mental Disorders, 4th Edition in the past 12 months;
10. Positive test result for fecal occult blood, measured at screening and/or at check-in to the clinic;
11. Consumption of alcohol within 48 hours prior to dosing;
12. Intake of more than 14 units (a unit is 12 oz beer, 5 oz wine, or 1.5 oz liquor) of alcohol per week;
13. Use of any drugs that induce or inhibit cytochrome P450 or P-glycoprotein within 30 days prior to dosing;
14. Use of any prescribed or over-the-counter (OTC) medications including antacids, analgesics, herbal remedies, vitamins, and minerals (with the exception of up to 3 grams of acetaminophen) or medications containing aspirin or nonsteroidal anti-inflammatory medications with anticoagulant effects within 2 weeks prior to dosing;
15. Any intake of grapefruit, grapefruit juice, Seville oranges, Seville orange marmalade, or other products containing grapefruit or Seville oranges within 7 days of dosing;
16. Planning to father a child or donate sperm during the study and 3 months following dosing;
17. Do not have veins suitable for cannulation or multiple venipunctures;
18. Have previously participated in this study;
19. Donation of plasma or blood products within 1 month of screening or any blood donation/blood loss greater than 450 mL during the 3 months prior to screening; or
20. Any other factor that the Investigator thinks will increase subject risk with participation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: TRIPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
PLACEBO_COMPARATOR: Placebo	Drug: GCC-4401C; Capsule, identical in appearance to GCC-4401C, for oral use; single dose; dosageCohort 1: 2.5-mg matching placeboCohort 2: 5.0-mg matching placeboCohort 3: 10-mg matching placeboCohort 4: 20-mg matching placeboCohort 5: 40-mg matching placeboCohort 6: 80-mg matching placebo
EXPERIMENTAL: Active	Drug: GCC-4401; Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use; single dose; dosageCohort 1: 2.5-mg GCC-4401CCohort 2: 5.0-mg GCC-4401CCohort 3: 10-mg GCC-4401CCohort 4: 20-mg GCC-4401CCohort 5: 40-mg GCC-4401CCohort 6: 80-mg GCC-4401C

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The number and percentage of subjects experiencing 1 or more AEs will be summarized by treatment/dose group, relationship to study drug, and severity.	up to 7 ~ 10 days after administraion
Statistics for clinical laboratory data(continuous variables only), vital signs, and ECF intervals will be presented for each evaluation during the study and for change from baseline to postdose evaluations.	up to 7 ~10 days after administration

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the single-dose pharmacokinetic behavior	to characterize the single-dose pharmacokinetic behavior after oral administration of GCC-4401C; maximum plasma concentration (Cmax);; time to Cmax (tmax);; terminal rate constant (λz);; area under the curve from zero to the time of the last measurable concentration [AUC(0-last)];; area under the curve from zero to infinity [AUC(0-inf)];; apparent terminal half-life (t½);; apparent systemic clearance (CL/F);; apparent volume of distribution (Vz/F);; renal clearance (CLr); and; fraction of drug (fe) excreted unchanged in urine (% of dose).	at predose and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, and 48 hours postdose

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
the single-dose pharmacodynamics behavior	PT;; aPTT;; INR;; coagulation factor X assay;; If the assay for coagulation factor X is abnormal a reflex inhibitor screen will be performed. This test will not be run on coagulation factor X assay results which are within normal range.; anti factor Xa assay;; escarin-stimulated thrombin activity; and; antithrombin (III) activity.	at predose and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 16, 24, and 48 hours postdose

Collaborators and Investigators

• Sponsor: Green Cross Corporation
• Collaborators: Quintiles, Inc.

Study record dates

Study Major Dates

• Study Start: March 1, 2012
• Primary Completion (ACTUAL): August 1, 2012
• Study Completion (ACTUAL): August 1, 2012

Study Registration Dates

• First Submitted: July 17, 2012
• First Submitted That Met QC Criteria: July 26, 2012
• First Posted (ESTIMATE): July 27, 2012

Study Record Updates

• Last Update Posted (ESTIMATE): August 29, 2012
• Last Update Submitted That Met QC Criteria: August 27, 2012
• Last Verified: August 1, 2012

More Information

Terms related to this study

• Other Study ID Numbers: GCC4401C-101